Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

• Autores: Monti Hughes, Andrea; Hu, Naonori
• Año de publicación: 2023
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: BNCT;; boron neutron capture therapy;; new boron compounds;; radiobiological studies;; strategies;; targeted therapy;; theranostic compounds.
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and StrategiesAndrea Monti Hughes 1 2, Naonori Hu 3 4Affiliations1Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina.2National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina.3Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.4Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan.AbstractBoron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
Fil: Monti Hughes, Andrea. Comisión Nacional de Energía Atómica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Hu, Naonori. Osaka Medical and Pharmaceutical University; Japón. Kyoto University; Japón